Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

  • Authors:
    • Chang‑Hua Kou
    • Tian Zhou
    • Xi‑Lin Han
    • Hui‑Jie Zhuang
    • Hai‑Xin Qian
  • View Affiliations

  • Published online on: October 14, 2016     https://doi.org/10.3892/ol.2016.5265
  • Pages: 4838-4844
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA‑23b (miR‑23b) expression in plasma on the diagnosis and prognosis of colorectal cancer (CRC). Reverse transcription-quantitative polymerase chain reaction (PCR) was used to measure miR‑23b expression levels, and methylation‑specific PCR was used to test the promoter methylation status. Subsequently, the expression level of miR‑23b in plasma samples was compared between CRC patients and healthy control individuals. The miR‑23b expression levels were significantly lower in CRC cells and primary CRC tissues than in nonmalignant colorectal tissues (P<0.001). It was also shown that miR‑23b expression is downregulated by promoter methylation and can be restored by demethylation agent treatment. miR‑23b was significantly decreased in plasma samples from CRC patients compared with the healthy control individuals (P<0.001). The value of the area under the receiver operating characteristic curve was 0.842 (sensitivity, 84.38%; specificity, 77.08%; 95% confidence interval, 0.763‑0.922). Low plasma miR‑23b expression was significantly associated with clinical stage, tumor depth, distant metastasis and tumor recurrence. CRC patients with low miR‑23b expression in plasma exhibited a shorter recurrence‑free survival time and poorer overall survival rate. The present results suggested that the downregulation of miR‑23b in the plasma has the potential to be a diagnostic and prognostic biomarker in CRC.
View Figures
View References

Related Articles

Journal Cover

December-2016
Volume 12 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kou CH, Zhou T, Han XL, Zhuang HJ and Qian HX: Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer. Oncol Lett 12: 4838-4844, 2016
APA
Kou, C., Zhou, T., Han, X., Zhuang, H., & Qian, H. (2016). Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer. Oncology Letters, 12, 4838-4844. https://doi.org/10.3892/ol.2016.5265
MLA
Kou, C., Zhou, T., Han, X., Zhuang, H., Qian, H."Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer". Oncology Letters 12.6 (2016): 4838-4844.
Chicago
Kou, C., Zhou, T., Han, X., Zhuang, H., Qian, H."Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer". Oncology Letters 12, no. 6 (2016): 4838-4844. https://doi.org/10.3892/ol.2016.5265